ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Abstract Number: 0039

Enrichment of Rare Variants of Hemophagocytic Lymphohistiocytosis Genes in Systemic Juvenile Idiopathic Arthritis
Abstract Number: 0039.5

Cytokine-induced Transcriptome Modification Elucidates the Similarity and Dissimilarity Across 10 Immune-related Diseases
Abstract Number: 0040

Non-canonical NF-κB Signalling Is Required for Extrathymic AIRE Expression and Immunoregulatory Molecules in Cells of the Dendritic Lineage
Abstract Number: 0041

Interactions Between Synovial Fibroblasts and Macrophages: Implications for Tissue Remodeling in Chronic Inflammatory Diseases and Macrophage Differentiation in Response to the Immune Microenvironment
Abstract Number: 0042

Effect of the Inflammatory Microenvironment Induced by Monocytes on Fibroblasts and Modulatory Action of Human Dental Pulp Stem Cells
Abstract Number: 0043

Assessing the Ability of Human Dental Pulp Stem Cells to Modulate the Macrophages Phenotype
Abstract Number: 0044

Aberrant Mevalonate Metabolite Farnesyl Pyrophosphate-Induced Neutrophil Hyperactivation in Behçet’s Disease Pathogenesis
Abstract Number: 0045

Discovery and Characterization of a Selective, Orally Bioavailable PAD4 Inhibitor to Target NETs Driven Autoimmune and Inflammatory Diseases
Abstract Number: 0046

Circulating Monocytes in RA, SSc, and SLE Have Radically Altered and Unique Transcriptional & Epigenetic Profiles
Abstract Number: 0047

Identification of Specific Monocyte Epigenetic Signatures in Sarcoidosis and Tuberculosis
Abstract Number: 0048

Monosodium Urate Crystals Activate an Immune Tolerance Program That Restrains the Activation of Inflammatory Signaling in Macrophages During Gout Flares
Abstract Number: 0049

Soluble Uric Acid Is an Endogenous Inhibitor of CD38
Abstract Number: 0050

Anti-Citrullinated Histone Antibody CIT-013, a Dual Action Therapeutic for Neutrophil Extracellular Trap Associated Autoimmune Disease
Abstract Number: 0051

CD14+CD64+ Classical Monocytes Are the Main Producers of IL-23 at the Enthesis
Abstract Number: 0052

Possible Involvement of TLR4 in the Pathogenesis of Primary Sjögren’s Syndrome Through Induction of the Expression of BAFF Receptor, BR3 in Peripheral Monocytes

« Previous Page
1
…
4
5
6
7
8
…
177
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].